Skip to main content
POOLBEG PHARMA PLC logo

POOLBEG PHARMA PLC — Investor Relations & Filings

Ticker · POLB ISIN · GB00BKPG7Z60 LEI · 213800UZ8WJLWYHBFL52 IL Manufacturing
Open in API
Filings indexed 160 across all filing types
Latest filing 2023-01-09 Regulatory Filings
Country GB United Kingdom
Listing IL POLB

About POOLBEG PHARMA PLC

https://poolbegpharma.com/

Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company that develops and commercializes medicines for diseases with high unmet medical needs. The company's lead asset, POLB 001, is a treatment designed to prevent Cytokine Release Syndrome (CRS), a severe side effect associated with cancer immunotherapies, with the aim of making these treatments safer and more accessible. Poolbeg is also advancing an oral GLP-1 program for obesity, offering a patient-friendly therapeutic option. The company utilizes an artificial intelligence (AI)-led discovery platform that analyzes data from human challenge trials to identify novel drug targets. This AI-driven approach aims to accelerate target identification, reduce costs, and lower development risks.

Recent filings

Filing Released Lang Actions
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document is very short (1935 characters) and contains the header 'RNS Number : 0853M'. It announces a 'Second Price Monitoring Extension' related to trading activity on the London Stock Exchange. It explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This indicates it is a general regulatory announcement disseminated via the RNS system, rather than a specific financial report like an ER, IR, or 10-K. Since it is a general regulatory announcement that doesn't fit the highly specific categories (like DIRS, DIV, or DLST), the most appropriate fallback is Regulatory Filings (RNS).
2023-01-09 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1918 characters) and its primary content is an announcement regarding a 'Price Monitoring Extension' for a security on the London Stock Exchange, referencing the 'RNS Number' and stating that the information is provided by RNS, the news service of the London Stock Exchange, which is approved by the Financial Conduct Authority (FCA). This structure—a brief notification about a market event or administrative update, explicitly mentioning RNS and regulatory approval—fits the definition of a general regulatory announcement that doesn't correspond to a specific financial report (like 10-K, ER, or IR). Therefore, the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for miscellaneous regulatory announcements.
2023-01-09 English
Positive Initial Data Analysis in POLB 001 Trial
Earnings Release Classification · 1% confidence The document starts with an 'RNS Number' and is dated '09 January 2023'. It contains a headline announcing 'Positive Initial Data Analysis in POLB 001 LPS Challenge Trial' and provides key highlights about clinical trial results. The text explicitly mentions that the full data read-out is expected later (Q2 2023), indicating this is an announcement of preliminary findings, not the final comprehensive report itself. The presence of the RNS header, the announcement format, and the nature of the content (clinical trial update) strongly suggest this is a general regulatory announcement disseminated via the London Stock Exchange's news service. Since it is a specific corporate update that doesn't fit the definitions for ER (Earnings Release), IR (Interim Report), or LTR (Legal Proceedings), the most appropriate classification is the general regulatory filing category, RNS. Q2 2023
2023-01-09 English
Poolbeg identifies novel RSV drug candidates
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 3928K' and contains standard boilerplate language referencing 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content is a press release announcing a scientific/drug development update (identifying new potential drug candidates for RSV using AI). This type of announcement, which is a general regulatory disclosure but not a specific financial report (like 10-K, IR, ER) or a specific corporate action (like DIV, DIRS, CAP), fits best into the general 'Regulatory Filings' category, which serves as the fallback for miscellaneous regulatory announcements not covered by more specific codes. Given the structure and source identification, RNS is the most appropriate code.
2022-12-21 English
Metabolic diseases oral delivery licence signed
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 6634J' and concludes with information about RNS, the news service of the London Stock Exchange, stating it is approved by the Financial Conduct Authority to act as a Primary Information Provider. This strongly indicates a regulatory news service announcement. The content details a significant business event: Poolbeg Pharma acquiring an exclusive license, announcing a future clinical trial, and adding a director to its Scientific Advisory Board. This type of material—a material, non-public announcement disseminated via an official channel like RNS—is typically classified as a general Regulatory Filing (RNS) if it doesn't fit a more specific category like Earnings Release (ER) or Director's Dealing (DIRS). Since it is a broad corporate update disseminated through the RNS system, RNS is the most appropriate general classification.
2022-12-14 English
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document explicitly starts with 'RNS Number' and mentions 'RNS, the news service of the London Stock Exchange' multiple times. The content describes a 'Second Price Monitoring Extension' related to trading activity, which is a specific type of market announcement. While it is a regulatory announcement, it is not a standard financial report (like 10-K or IR) or a specific corporate action like a dividend or director dealing. Given the context of being an immediate, non-standard market notice distributed via the RNS system, and lacking a more specific category, the most appropriate classification is the general Regulatory Filings category (RNS). The document length is short (1936 chars), but it is the primary content itself, not an announcement *about* another report, so the RPA rule does not strictly apply here, although RNS is often used for these immediate trading notices.
2022-12-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.